Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Receivables (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Change in Receivables for 3 consecutive years, with -$935000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables fell 78.78% to -$935000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$204000.0, a 950.0% decrease, with the full-year FY2024 number at -$381000.0, down 171.21% from a year prior.
  • Change in Receivables was -$935000.0 for Q3 2025 at Inhibrx Biosciences, down from $872000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $872000.0 in Q2 2025 to a low of -$935000.0 in Q3 2025.
  • A 3-year average of -$19555.6 and a median of $4000.0 in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: plummeted 13175.0% in 2024, then soared 270.98% in 2025.
  • Inhibrx Biosciences' Change in Receivables stood at $447000.0 in 2023, then crashed by 90.6% to $42000.0 in 2024, then tumbled by 2326.19% to -$935000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Change in Receivables are -$935000.0 (Q3 2025), $872000.0 (Q2 2025), and -$183000.0 (Q1 2025).